Abstract
We investigated the effect of c-myb antisense phosphorothioate oligodeoxynucleotides [(S)ODNs] and cisplatin (CDDP) combination on the human colon carcinoma cell line LoVo Dx both in vitro and in nude mice bearing LoVo Dx solid tumour. We show that antisense (S)ODN treatment decreases c-myb mRNA and protein expression, induces growth arrest in the G1 phase of the cell cycle, and inhibits cell proliferation. In vivo treatment with c-myb antisense (S)ODNs results in a reduction in tumour growth. A greater inhibition of cell proliferation in vitro and a higher increase of tumour growth inhibition and growth delay in vivo were obtained with the combination of (S)ODNs and CDDP than when the two agents were administered separately. This comparative study, using the same tumour cell line in vitro and in vivo, suggests that c-myb antisense (S)ODNs might be useful in the therapy of colon cancer in combination with antineoplastic drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Del Bufalo, D., Cucco, C., Leonetti, C. et al. Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br J Cancer 74, 387–393 (1996). https://doi.org/10.1038/bjc.1996.370
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.370
This article is cited by
-
p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK
Cell Death & Differentiation (2004)
-
The future of antisense therapy: combination with anticancer treatments
Oncogene (2003)
-
Antisense cancer therapy: The state of the science
Current Oncology Reports (2000)
-
Clinical evaluation of biologically targeted drugs: Obstacles and opportunities
Cancer Chemotherapy and Pharmacology (1998)